enGene Holdings Inc. (NASDAQ:ENGNW) Short Interest Update

enGene Holdings Inc. (NASDAQ:ENGNW) was the recipient of a significant growth in short interest in the month of March. As of March 31st, there was short interest totalling 4,800 shares, a growth of 4,700.0% from the March 15th total of 100 shares. Based on an average daily volume of 10,400 shares, the days-to-cover ratio is currently 0.5 days.

enGene Price Performance

enGene stock opened at $0.65 on Tuesday. The firm has a 50-day moving average of $0.73 and a two-hundred day moving average of $1.12. enGene has a 1 year low of $0.42 and a 1 year high of $4.70.

enGene Company Profile

enGene Holdings Inc, through its subsidiary enGene, Inc, operates as a clinical-stage biotechnology company that develops genetic medicines through the delivery of therapeutics to mucosal tissues and other organs. Its lead product candidate is EG-70 (detalimogene voraplasmid), which is a non-viral immunotherapy to treat non-muscle invasive bladder cancer patients with carcinoma-in-situ (Cis), who are unresponsive to treatment with Bacillus Calmette-Guérin.